Compare STEX & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STEX | CGTX |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | 6 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.7M | 110.8M |
| IPO Year | N/A | 2021 |
| Metric | STEX | CGTX |
|---|---|---|
| Price | $0.94 | $1.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $9.00 | $3.33 |
| AVG Volume (30 Days) | ★ 1.4M | 1.0M |
| Earning Date | 05-17-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,044.81 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $0.22 |
| 52 Week High | $7.44 | $3.83 |
| Indicator | STEX | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.06 | 54.57 |
| Support Level | $0.70 | $1.19 |
| Resistance Level | $1.16 | $1.36 |
| Average True Range (ATR) | 0.15 | 0.10 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 42.35 | 36.96 |
Streamex Corp is a vertically integrated technology and infrastructure company. The Company is a technology company with two principal lines of business: (i) Tokenized Asset Finance, focused on digital asset and real-world asset tokenization via Streamex Exchange platform, and (ii) Biomedical Technology, focused on signal processing solutions in electrophysiology. The group provides institutional-grade solutions that bring traditional commodities and assets on-chain through secure, regulated, and yield-bearing financial instruments. It is committed to delivering transparent, scalable, and compliant digital asset solutions that bridge the gap between traditional finance and blockchain-enabled markets.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).